The role of arginine, homoarginine and nitric oxide in pregnancy
Authors:
- 20 June 2015
- journal article
- review article
- Published by Springer Nature in Amino Acids
- Vol. 47 (9) , 1715-1727
Abstract
Normal pregnancy leads to profound maternal hemodynamic changes, including increased blood volume and vasodilatation. Several vasodilator mediators are implicated, including prostaglandins, carbon monoxide and nitric oxide (NO). Pre-eclampsia (PE) affects 3–10 % of pregnancies and is associated with increased maternal and perinatal morbidity and mortality. Around 8 % of pregnancies are complicated by intra-uterine growth restriction (IUGR), also associated with increased perinatal mortality and morbidity. PE and IUGR often co-exist. NO is essential for the formation of healthy endothelium, and in pregnancy promotes endovascular invasion by the cytotrophoblast. As interstitial trophoblasts invade the maternal spiral arteries in the uterine wall, they produce NO which acts on artery walls to create a low-resistance, high-caliber uteroplacental unit. If this process fails, the result is a high-resistance uteroplacental circulation. The hypoperfused and ischemic placenta releases antiangiogenic factors which mediate generalized endothelial dysfunction, oxidative stress and inflammatory mediators. It is these mediators that are implicated in both the fetal and maternal syndromes of PE and IUGR. Studies of NO and its modulator amino acids, including the precursors arginine and homoarginine and the NO synthesis inhibitor asymmetric dimethylarginine (ADMA), have investigated their role in both normal and pathological pregnancies. Many studies of PE (and, to a lesser extent, IUGR) have investigated maternal circulating ADMA, arginine and homoarginine levels. This article reviews and discusses the role of these amino acids in pregnancy. The results have shed some light on their role in these pathologies, but some of the findings have been conflicting and more research is needed. Nevertheless, therapeutic interventions that manipulate these guanidine–amino acids and their interactions hold real promise for the management of pregnancies complicated by PE and/or IUGR, and the results of ongoing studies are eagerly awaited.Keywords
This publication has 120 references indexed in Scilit:
- Assessment of l-arginine asymmetric 1 dimethyl (ADMA) in early-onset and late-onset (severe) preeclampsiaNitric Oxide, 2013
- The Global Impact of Pre-eclampsia and EclampsiaSeminars in Perinatology, 2009
- Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infantsAmerican Journal of Obstetrics and Gynecology, 2008
- Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJ, 2007
- Asymmetric dimethylarginine (ADMA)—A modulator of nociception in opiate tolerance and addiction?Nitric Oxide, 2007
- Elevatedl-Arginine/Dimethylarginine Ratio Contributes to Enhanced Systemic NO Production by Dietaryl-Arginine in Hypercholesterolemic RabbitsBiochemical and Biophysical Research Communications, 1996
- Nitric Oxide Protects Against Leukocyte-Endothelium Interactions in the Early Stages of HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Estrogen Increases Endothelial Nitric Oxide by a Receptor Mediated SystemBiochemical and Biophysical Research Communications, 1995
- Growth and neurodevelopmental outcome of very low birth weight infants with intrauterine growth retardation: Comparison with control subjects matched by birth weight and gestational ageThe Journal of Pediatrics, 1993
- A practical classification of newborn infants by weight and gestational ageThe Journal of Pediatrics, 1967